Please use this identifier to cite or link to this item:
https://nslhd.intersearch.com.au/nslhdjspui/handle/1/31670
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Guo, Lesley | en |
dc.contributor.author | Kneebone, A. | en |
dc.contributor.author | Eade, Thomas N. | en |
dc.date.accessioned | 2021-06-17T07:47:52Z | - |
dc.date.available | 2021-06-17T07:47:52Z | - |
dc.date.issued | 2013-10 | - |
dc.identifier.citation | 57(S1):34 | en |
dc.identifier.uri | https://nslhd.intersearch.com.au/nslhdjspui/handle/1/31670 | - |
dc.description.abstract | Purpose: To report late radiation toxicity in a contemporary cohort of patients treated exclusively with high dose radiotherapy, daily image guidance and Intensity Modulated Radiation Therapy (IMRT) or Intensity Modulated Arc Therapy (IMAT). Methods and Materials: Patients were followed prospectively using a real time database which included toxicity reported using the modified RTOG scale. The current study included all patients treated between April 2007 and April 2012 with a minimum 12 months follow up. Patients were planned with either 7-9 field IMRT or IMAT. Rectal and bladder planning goals remained unchanged (rectal V65 < 17%, V40 < 35%; bladder V65 < 25% and V40 < 50%). Daily image guidance was used for all patients. Baseline urinary function was assessed with the international prostatic symptom score (IPSS). Late toxicity was estimated using Kaplan Meier statistics. Results: There were a total of 239 patients eligible for analysis with a median age of 72 yrs (46 yrs to 84 yrs). There were 26 diabetic patients (11%). The median IPSS prior to treatment was 6 (0-31). The majority of the patients were either intermediate risk (40%) or high risk (52%). There were 8 patients (3.3%) who had known lymph node metastases. Androgen deprivation was used in 66% of patients (19% short term and 37% long term) and 34% of the patients had pelvic lymph node irradiation with a synchronous boost (56 Gy-60 Gy in 38-40#). Mean delivered dose to the PTV was 79 Gy/38# (n= 102); 81 Gy/39# (n=16) and 83 Gy/40# (n=121). The 3 yr late gastrointestinal and genitourinary cumulative Grade 2+ toxicities were 3.2% and 13.9% respectively. A comparison of the high and low dose cohorts respectively for rectal toxicity (1.8% vs. 4.3%) and bladder toxicity (16.5% vs. 12%) was similar. Conclusion: Doses above 80 Gy can be delivered safely for prostate cancer using daily IGRT combined with IMRT/IMAT. | en |
dc.language | en | en |
dc.language.iso | en | en |
dc.relation.ispartof | Journal of Medical Imaging and Radiation Oncology | en |
dc.title | High dose prostate cancer radiotherapy: Late toxicity outcomes | en |
dc.type | Conference presentation | en |
dc.identifier.affiliation | Royal North Shore Hospital | en |
dc.identifier.doi | 10.1111/1754-9485.12117 | - |
dc.description.pages | 34 | en |
dc.relation.url | https://onlinelibrary.wiley.com/doi/epdf/10.1111/1754-9485.12117 | en |
dc.subject.keywords | Male | en |
dc.subject.keywords | patient | en |
dc.subject.keywords | bladder | en |
dc.subject.keywords | intensity modulated radiation therapy | en |
dc.subject.keywords | risk | en |
dc.subject.keywords | follow up | en |
dc.subject.keywords | data base | en |
dc.subject.keywords | Humans | en |
dc.subject.keywords | low drug dose | en |
dc.subject.keywords | lymph node irradiation | en |
dc.subject.keywords | Radiotherapy | en |
dc.subject.keywords | pelvis lymph node | en |
dc.subject.keywords | lymph node metastasis | en |
dc.subject.keywords | radiation | en |
dc.subject.keywords | diabetic patient | en |
dc.subject.keywords | statistics | en |
dc.subject.keywords | International Prostate Symptom Score | en |
dc.subject.keywords | planning | en |
dc.subject.keywords | image guided Radiotherapy | en |
dc.subject.keywords | androgen | en |
dc.subject.keywords | drug megadoseprostate cancer | en |
dc.subject.keywords | cancer Radiotherapy | en |
dc.subject.keywords | toxicity | en |
dc.subject.keywords | New Zealand | en |
dc.subject.keywords | college | en |
dc.subject.keywords | radiologist | en |
dc.relation.conference | 64th Annual Scientific Meeting of the Royal Australian and New Zealand College of Radiologists, RANZCR 2013. Auckland New Zealand | en |
dc.subject.aht | Radiotherapy | en |
dc.subject.aht | Prostate Cancer | en |
dc.subject.aht | Toxicity | en |
local.editedby.name | NW 3/12/2021 | en |
dc.relation.department | Northern Sydney Cancer Centre | en |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.fulltext | No Fulltext | - |
item.languageiso639-1 | en | - |
item.openairetype | Conference presentation | - |
item.cerifentitytype | Publications | - |
item.grantfulltext | none | - |
crisitem.author.dept | Northern Sydney Cancer Centre | - |
crisitem.author.dept | Royal North Shore Hospital | - |
crisitem.author.dept | Radiation Oncology | - |
crisitem.author.dept | Northern Sydney Cancer Centre | - |
crisitem.author.dept | Radiation Oncology | - |
crisitem.author.dept | Royal North Shore Hospital | - |
crisitem.author.dept | Northern Sydney Cancer Centre | - |
crisitem.author.dept | Royal North Shore Hospital | - |
crisitem.author.dept | Radiation Oncology | - |
Appears in Collections: | Research Publications |
Items in NSLHD are protected by copyright, with all rights reserved, unless otherwise indicated.